Bayer buoyed by success in late-stage clotting trial

Shares of Bayer were buoyed after researchers announced that an experimental anti-clotting therapy was just as safe but considerably more effective than Sanofi-Aventis' Lovenox in a Phase III trial involving knee-surgery patients. That was crucial news for Bayer, which has tapped rivaroxaban as a blockbuster badly needed to pump new revenue into Germany's biggest drug maker. Volunteers taking the drug saw their risk of developing deep-vein thrombosis cut in half when compared to the Lovenox arm of the trial.

Bayer now expects to file for European approval later this year with an FDA application in 2008. That puts them ahead of BMS and Pfizer to develop a new clotting therapy.

- see this release for more
- read the AFX report on the trial results

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.